Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)


An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension




The purpose of this study is to see whether the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson`s Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.

Study Status: Completed


Condition Intervention Phase
Neurogenic Orthostatic Hypotension
Non-Diabetic Autonomic Neuropathy
Multiple System Atrophy
Dopamine Beta Hydroxylase Deficiency
Drug: Droxidopa
Drug: Placebo
Phase 3

Verified by Chelsea Therapeutics March, 2013

Sponsored by: Chelsea Therapeutics
Information provided by: Chelsea Therapeutics identifier: NCT00738062

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Horacio Kaufmann Kaufmann, MD., Principal Investigator
Christopher J. Mathias, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site